Karim Sayed MD

The elective use of hyaluronidase

Saturday 19th November, 16:15


A key features of hyaluronic acid (HA) dermal fillers underlying their success is reversibility. The injectable enzyme hyaluronidase (HYAL) cleaves the HA chains present in HA gel fillers, permitting diffusion and further degradation by native hyaluronidases. In contrast to high-dose protocols for vascular compromise where the goal is rapid an complete dissolution of product, elective use of HYAL requires a more tailored and/or targeted approach. This presentation details elective uses of HYAL, including management of misplaced product, micro doses for reduction of product volume, as well as the resolution of early and late-onset nodules. The talk will also review ultrasound guided management of these issues.

Dr Karim Sayed graduated from University of Oslo Medical School in 2003 and is a KOL in the Nordics. 

Dr Sayed is aesthetic doctor with 13 years of experience in aesthetic medicine and in addition to running his own clinic in downtown Oslo, he is a lecturer at the University of Southeast Norway where he teaches in the field of aesthetic medicine. 

He has 8 years of experience as a trainer, and hosts multiple trainings masterclasses yearly, on subjects like Botulinum Toxin type A, advanced filler treatments and laser treatments. 

He has a particular interest in complications and sees patients with complications from all over Norway, and is Allergan´s official complications consultant in Norway.  He is also a part of Allergan´s European complications group. 

Dr Sayed  is famous in Norway for both his teaching and his skills as an aesthetic practitioner, and has treated thousands of patients there. 

He is also the co-founder and current chairman of NORFEM (the Association of Aesthetic Practitioners in Norway).